Core Viewpoint - Robbins LLP is investigating Kindercare Learning Companies, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1]. Group 1: Company Overview - Kindercare Learning Companies, Inc. provides early childhood education and care services in the United States [1]. Group 2: Legal Investigation - The investigation by Robbins LLP aims to determine if there were any violations of securities laws by Kindercare's officers and directors [1]. - Shareholders who have lost money in their investment in Kindercare are encouraged to contact Robbins LLP for more information about their rights [2]. Group 3: Robbins LLP Background - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, having obtained over $1 billion for shareholders [3].

Group 1 - Robbins LLP is investigating BellRing Brands, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1] - BellRing Brands manufactures and sells nutrition products both in the U.S. and internationally [1] - Shareholders who have lost money in their investment in BellRing Brands are encouraged to contact Robbins LLP for more information about their rights [1] Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [2] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, having obtained over $1 billion for shareholders [2] Group 3 - Shareholders can sign up for alerts regarding class action settlements or corporate executive wrongdoing related to BellRing Brands [3]

Core Viewpoint - A class action lawsuit has been filed against XPLR Infrastructure LP (NYSE: XIFR) on behalf of investors who acquired its securities between September 27, 2023, and January 27, 2025, due to allegations of misleading information regarding its yieldco business model [1][2]. Group 1: Allegations and Business Model - The complaint alleges that XPLR was struggling to maintain its operations as a yieldco and had entered into financing arrangements while downplaying associated risks [2]. - It is claimed that XPLR could not resolve its financing issues before maturity without risking significant unitholder dilution, leading to plans to halt cash distributions to investors [2]. - The sustainability of XPLR's yieldco business model and distribution growth rate was called into question due to these issues [2]. Group 2: Strategic Changes and Market Reaction - On January 28, 2025, XPLR announced it was abandoning its yieldco business and indefinitely suspending cash distributions to unitholders, shifting to a model utilizing retained operating cash flows for investments [3]. - Following this announcement, XPLR's common unit price fell from $15.80 on January 27, 2025, to $10.49 on January 29, 2025, marking a decline of $5.31 per unit, or nearly 35% [3]. Group 3: Legal Proceedings - Shareholders interested in participating in the class action must file their papers with the court by September 8, 2025, to serve as lead plaintiff [4]. - A lead plaintiff acts on behalf of other class members in directing the litigation, but participation is not required for recovery eligibility [4].

Core Viewpoint - A class action has been filed against iRobot Corporation (NASDAQ: IRBT) on behalf of investors who acquired its securities between January 29, 2024, and March 11, 2025, due to allegations of misleading statements regarding the impact of the termination of Amazon's acquisition [1][2]. Group 1: Allegations and Company Actions - iRobot and Amazon mutually agreed to terminate the acquisition in January 2024, yet iRobot claimed confidence in its ability to operate successfully as a standalone company [2]. - Following the acquisition termination, iRobot announced a Restructuring Plan, referred to as "iRobot Elevate," aimed at stabilizing the company and focusing on profitability and growth in mid-tier and premium segments [2][3]. - On March 12, 2025, iRobot reported disappointing financial results for Q4 and full year 2024, leading to a significant stock price drop of $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [2]. Group 2: Financial Stability Concerns - The plaintiff alleges that iRobot overstated the effectiveness of the Restructuring Plan, suggesting that the company would struggle to operate profitably as a standalone entity [3]. - There are claims of substantial doubt regarding iRobot's ability to continue as a going concern due to the misleading statements made during the class period [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action against iRobot Corporation must contact the firm before September 5, 2025, to serve as lead plaintiff [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4].

Core Viewpoint - A class action has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, during the period from June 22, 2023, to June 24, 2025 [1][2]. Allegations - The complaint alleges that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific incidents include a patient death reported on March 18, 2025, leading to a stock price drop of $27.81 per share (27.44%) to close at $73.54 [3]. - A second patient death due to acute liver failure was disclosed on June 15, 2025, resulting in a further stock price decline of $15.24 per share (42.12%) to close at $20.91 [3]. - Following an FDA investigation announcement regarding acute liver failure risks on June 24, 2025, Sarepta's stock fell by $1.52 per share (8.01%) to close at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file a motion by August 25, 2025, but can remain absent class members without taking action [5].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. due to allegations of deceptive promotion and sale of illegitimate versions of Wegovy®, leading to a significant drop in the company's stock price [2][3]. Group 1: Allegations and Impact - Hims & Hers Health, Inc. announced a collaboration with Novo Nordisk on April 29, 2025, to sell Wegovy® on its platform [2]. - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing deceptive practices that jeopardized patient safety, resulting in a 34.6% decline in Hims' share price, closing at $41.98 [2]. - The lawsuit claims that Hims failed to disclose its engagement in selling illegitimate versions of Wegovy® and the risk of partnership termination with Novo Nordisk [3]. Group 2: Legal Proceedings - Shareholders interested in leading the class action must file a motion by August 25, 2025, and can remain absent class members if they choose not to participate [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for allegedly misleading investors about its business prospects and financial performance during the specified period [1][2]. Allegations - The lawsuit claims that DoubleVerify did not disclose significant shifts in customer ad spending from open exchanges to closed platforms, where the company's capabilities were limited [2]. - It is alleged that the company’s ability to monetize its Activation Services was constrained due to the high costs and time required for technology development for closed platforms [2]. - The complaint states that monetization of Activation Services related to certain closed platforms would take several years, impacting revenue generation [2]. - Competitors were reportedly better positioned to integrate AI into their offerings on closed platforms, which negatively affected DoubleVerify's competitive stance and profitability [2]. - The company is accused of systematically overbilling customers for ad impressions served to bots operating from known data centers [2]. - The risk disclosures provided by DoubleVerify were claimed to be materially false and misleading, as they downplayed adverse facts that had already occurred [2]. Impact of Disclosure - The truth about DoubleVerify's business challenges was revealed on February 27, 2025, when the company reported lower-than-expected sales and earnings for Q4 2024, attributed to reduced customer spending and service suspension by a major client [3]. - Following this disclosure, DoubleVerify's stock price fell by $7.83, or 36%, from $21.73 to $13.90 within a day [3]. Next Steps for Shareholders - Shareholders interested in participating in the class action must file their papers by July 21, 2025, to serve as lead plaintiffs [4]. - Shareholders can choose to remain absent class members without participating in the case [4]. About Robbins LLP - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5].

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Vestis Corporation (NYSE:VSTS) securities between May 2, 2024, and May 6, 2025, alleging that the company misled investors regarding its customer growth and strategic initiatives [1][2]. Allegations - The complaint asserts that Vestis Corporation failed to disclose its inability to execute planned strategic initiatives aimed at improving customer experience and onboarding, which were expected to drive new customer growth and retention [2]. - It is claimed that these misleading statements led investors to purchase Vestis securities at artificially inflated prices [2]. Financial Results and Market Reaction - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year, and provided third-quarter guidance that significantly missed market expectations [3]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [3]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Participation - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4].

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024 and March 3, 2025. PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The Company’s lead product candidate was PGN-EDO51, a proprietary enhanced deliv ...